Please login to the form below

Not currently logged in
Email:
Password:

Kirin USD 1.5bn takeover bid for Kyowa Hakko

Japanese brewer Kirin has placed a USD 1.5bn bid for pharmaceutical company Kyowa Hakko Kogyo, which has accepted the offer

Japanese brewer Kirin has placed a USD 1.5bn bid for pharmaceutical company Kyowa Hakko Kogyo, which has accepted the offer.

Kirin will merge its pharmaceutical unit with Kyowa Hakko in 2008.

Kirin will purchase 50.1 per cent of Kyowa's outstanding shares through public bidding and swapping Kirin with Kyowa Hakko shares, according to a joint statement.

Of the 50.1 per cent acquired, Kirin will then buy 28 per cent, or 111,578,000 shares in Kyowa through the public bidding.

Kirin is offering to buy Kyowa shares at JPY 1,500 (USD 13.17) each, or 7.6 per cent higher than the share's last trading price, which puts the total value of bidding at JPY 167.4bn (USD 1.5bn).

Japanese breweries have been diversifying to offset slowed growth, as consumers have changed their drinking habits; switching to wine and other alcoholic beverages.

Kyowa Hakko's stock fell 0.57 per cent to rest at JPY 1,394 (USD 12.20) on the Tokyo Stock Exchange in a.m. trading on 22 October, a better performance than the 3.2 per cent drop in the key Nikkei-225 index following heavy losses on Wall Street.

Kyowa will become a consolidated subsidiary of Kirin in April 2008 and will have a combined drug business revenue of about JPY 200bn, putting it on par with the industry's 10th-largest company, Shionogi.

Kyowa and Kirin will merge on 1 October 2008 to create Kyowa Hakko Kirin, led by Kyowa Hakko's president, Yuzuru Matsuda.

Kirin president Kazuyasu Kato said at a news conference: "We aim to be a Japanese company that is strong in research and development and can vie with the world's top firms."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics